Profle of Xeomin®(incobotulinumtoxina) for the treatment of blepharospasm

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Even though conventional botulinum neurotoxin (BoNT) products have shown successful treatment results in patients with benign blepharospasm (BEB), the main, potential long-term side effect of BoNT use is the development of immunologic resistance due to the production of neutralizing antibody to the neurotoxin after repeated injections. Xeomin® (incobotulinumtoxina), a unique botulinum neurotoxin type A (BoNT/A) drug free of complexing proteins otherwise contained in all conventional BoNT/A drugs, was recently approved by US Food and Drug Administration for the treatment of cervical dystonia or blepharospasm in adults. The newly approved BoNT/A drug may overcome this limitation of previous conventional products, since it contains pure neurotoxin (150 kDa) through a manufacturing process that separates it from complexing proteins such as hemagglutinins produced by fermentation of Clostridium botulinum. Many studies have also shown that Xeomin® has the same effcacy and safety profle as complexing protein-containing products such as Botox® and is exchangeable with Botox® using a simple 1:1 conversion ratio. Xeomin® represents a new treatment option for the repeated treatment of patients with blepharospasm in that it may reduce antibody-induced therapy failure. But, long-term comparative trials in naïve patients between Xeomin® and conventional BoNT/A drugs are required to confrm the low immunogenicity of Xeomin®.

Original languageEnglish (US)
Pages (from-to)725-732
Number of pages8
JournalClinical Ophthalmology
Issue number1
StatePublished - 2011


  • Blepharospasm
  • Botulinum neurotoxin type a
  • Complexing proteins
  • Incobotulinumtoxina
  • Neutralizing antibodies
  • Xeominspi_sup®spii_sup


Dive into the research topics of 'Profle of Xeomin®(incobotulinumtoxina) for the treatment of blepharospasm'. Together they form a unique fingerprint.

Cite this